MedTrace Logo

Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

NCT07075718 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 610

Last updated 2026-03-02

No results posted yet for this study

Summary

Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Conditions

Interventions

DRUG

Gen 2 Travoprost Intracameral Implant

travoprost

DRUG

Timolol eye drops 0.5%

timolol 0.5%

PROCEDURE

Sham Procedure

sham implant administration

OTHER

Placebo eye drops

artificial tears

Sponsors & Collaborators

  • Glaukos Corporation

    lead INDUSTRY

Principal Investigators

  • Luis G. Vargas, MD · Glaukos Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-12
Primary Completion
2028-03-31
Completion
2032-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07075718 on ClinicalTrials.gov